RAD54L and Miyoshi myopathy: The MTS assay revealed significant decreased in proliferation of MM cells treated with RAD54L siRNA compared to the control siRNA at 48 h (P < 0.01) and 72 h (P < 0.05) post-transfection (Fig. 2C).